Clinical Trials

Phase 1/2 Active not recruiting

Leukemia, Myeloid, Acute

NCT07148947 2026-03-04

Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms

Phase 2 Recruiting

27 enrolled

Myeloid

Accelerated Phase Myeloproliferative Neoplasm

NCT06297629 2026-02-24

A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation

Phase 2 Withdrawn

Allogeneic Stem Cell Transplantation

NCT04655755 2026-02-18

Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

52 enrolled

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT05007873 2026-02-18

ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase

Phase 2 Recruiting

70 enrolled

Leukemia, Myeloid, Chronic-Phase

NCT06191978 2026-02-18

A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)

40 enrolled

Classical hematologyMyeloid

Leukemia, Myeloid, Acute

NCT06284460 2026-02-13

Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms

Phase 1/2 Withdrawn

Anemia, Refractory, with Excess of Blasts, Myeloproliferative Disorders

NCT04872543 2026-02-05

A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)

Phase 2 Recruiting

25 enrolled

Sarcoma

Neurofibrosarcoma

NCT06177171 2026-02-02

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

18 enrolled

BRCA1 Mutation

NCT05010772 2026-01-14

Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission

125 enrolled

Leukemia, Myeloid, Acute

NCT06327685 2026-01-08

Avapritinib With Decitabine in Patients With SM-AHN

34 enrolled

Phase 1 Active not recruiting

Systemic Mastocytosis With an Associated Hematologic Neoplasm

NCT03613532 2025-12-24

Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN

102 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT03922555 2025-12-18

ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas

Phase 1/2 Active not recruiting

18 enrolled

CNS

Central Nervous System Neoplasms

NCT05089370 2025-12-08

Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma

8 enrolled

Dermatologic

Melanoma

NCT05178693 2025-11-24

LANTana

27 enrolled

EndocrineNET

Neuroendocrine Tumors

NCT05037500 2025-11-12

Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer

Phase 1 Terminated

8 enrolled

Genitourinary

Prostatic Neoplasms

NCT04774393 2025-11-10

Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Phase 1/2 Recruiting

84 enrolled

Leukemia, Myeloid, Acute

NCT05360160 2025-10-23

A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

Phase 1/2 Recruiting

43 enrolled

Phase 1 Active not recruiting

Leukemia, Myeloid, Acute

NCT05396859 2025-10-20

Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia

13 enrolled

Leukemia, Myeloid, Acute

NCT02998567 2025-08-17

HyPeR

Phase 1 Active not recruiting

60 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04980404 2025-07-20

Inqovi Maintenance Therapy in Myeloid Neoplasms

22 enrolled

Phase EARLY_PHASE1 Recruiting

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myelomonocytic, Chronic

NCT06802146 2025-03-27

Early Intervention in High Risk CCUS

108 enrolled

Classical hematology

Cytopenia

NCT06351306 2025-03-24

DEC-C and Thioguanine for R/R AML

Phase 2 Withdrawn

Neoplasms, Leukemia, Myeloid, Acute

NCT06113289 2025-03-12

A Phase 1B/2A Trial of Combination of ASTX727 With ASTX029 in Acute Myeloid Leukemia

Phase 1/2 Withdrawn

Leukemia, Myeloid, Acute

NCT06357858 2024-07-03

ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck

Phase 1 Withdrawn

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT04134884 2024-03-22

Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer

Phase 1 Completed

34 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04013880 2020-07-07

ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia

Phase 1/2 Withdrawn